Skip to content
DraconiticResearch
Search Sources API
182,469 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYnpj Breast Cancer

Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer

  • William S. O. Symmans1
  • Kevin Tran1
  • Chunxiao Fu1
  • Hongxia Sun1
  • Rebekah Gould1
  • Lajos Pusztai2
  • Tari King3
  • Roberto Salgado4
  • Vicente Valero1
  • W. Fraser Symmans1
  • Eleni Andreopoulou5
5 affiliations
  1. 1The University of Texas MD Anderson Cancer Center
  2. 2Yale University
  3. 3Winship Cancer Institute, Emory University
  4. 4ZAS Hospitals
  5. 5Weill Cornell Medicine
Read full textPDFDOICite

Abstract

It is important to understand how the biology of breast cancer might differ with the burden of disease. Analyzing the expression of cancer-relevant genes with increasing diagnostic stage can provide insight into the changing biology of breast cancer and may also be clinically useful. Here, we evaluated the transcriptional activity according to the stage of breast cancer (American Joint Committee on Cancer, AJCC Stage I to IV) from 1152 patients with hormone receptor-positive HER2-negative breast cancer. Fresh tumor samples were prospectively collected for clinical-translational research with transcriptional profiling. Most transcriptional signatures remained consistent across stage categories, but the significant changes associated with increasing stage were attributed to endocrine escape, decreasing differentiation, increased complexity of signal transduction, and a few metabolic changes. The clinical relevance and implications of these findings are discussed. The expression data from these high-quality samples are a new publicly available resource for researchers.

Related

  1. Multiparametric MRI-based radiomics for differentiating HER2-negative, HER2-low, and HER2-positive breast cancer
    Lulu Gai, Shubin Luo, Yudong Yan +9
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
    Anna-Christina Rambow, Tim Jannik Schröder, Gudrun Wagenpfeil +6
    Breast care (Basel, Switzerland)Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Changes in positive mental health before and after the COVID-19 pandemic and its associated sociodemographic characteristics and COVID-19-related stressors
    Sajedeh Nejatian, Xiang Wang, Yingying Su +8
    Canadian Journal of Public Health = Revue Canadienne de Santé PubliquePeer-reviewedLicence not statedFull text1 citedPsychiatry & mental healthPMC
  4. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis.
    Binliang Liu, Tao Wu, Fang Xu +7
    Health economics reviewPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
  5. Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
    Jean-Louis Lacaze, Bastien Cabarrou, Thibaut Cassou-Mounat +10
    The OncologistPeer-reviewedCC BY-NC 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{symmans2026stagerelated,
  title = {{Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer}},
  author = {William S. O. Symmans and Kevin Tran and Chunxiao Fu and Hongxia Sun and Rebekah Gould and Lajos Pusztai and Tari King and Roberto Salgado and Vicente Valero and W. Fraser Symmans and Eleni Andreopoulou},
  journal = {npj Breast Cancer},
  year = {2026},
  month = jul,
  doi = {10.1038/s41523-026-00973-6},
  url = {https://doi.org/10.1038/s41523-026-00973-6},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer
AU  - William S. O. Symmans
AU  - Kevin Tran
AU  - Chunxiao Fu
AU  - Hongxia Sun
AU  - Rebekah Gould
AU  - Lajos Pusztai
AU  - Tari King
AU  - Roberto Salgado
AU  - Vicente Valero
AU  - W. Fraser Symmans
AU  - Eleni Andreopoulou
PY  - 2026
DA  - 2026/07/01
JO  - npj Breast Cancer
DO  - 10.1038/s41523-026-00973-6
UR  - https://doi.org/10.1038/s41523-026-00973-6
AB  - It is important to understand how the biology of breast cancer might differ with the burden of disease. Analyzing the expression of cancer-relevant genes with increasing diagnostic stage can provide insight into the changing biology of breast cancer and may also be clinically useful. Here, we evaluated the transcriptional activity according to the stage of breast cancer (American Joint Committee on Cancer, AJCC Stage I to IV) from 1152 patients with hormone receptor-positive HER2-negative breast cancer. Fresh tumor samples were prospectively collected for clinical-translational research with transcriptional profiling. Most transcriptional signatures remained consistent across stage categories, but the significant changes associated with increasing stage were attributed to endocrine escape, decreasing differentiation, increased complexity of signal transduction, and a few metabolic changes. The clinical relevance and implications of these findings are discussed. The expression data from these high-quality samples are a new publicly available resource for researchers.
SN  - 2374-4677
ER  -